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outcomes of patients with paradoxical worsening in tuberculous
lymphadenitis.
Methods & Materials: Between 2008-2012, 124 patients were
seen in ID Clinic with a diagnosis of probable Tuberculous Lym-
phadenitis. HIV positive and proven MDR tuberculosis patients
were excluded. 36 patients with PR were identiﬁed based on
appearance of new nodes or enlargement of pre-existing nodes
with ﬂuctuation or discharge while on treatment. Univariate anal-
ysis was done to identify factors associated with PR.
Results: 52 were men with 13 in PR group and 72 were women
with 23 in PR group. Mean baseline ESR was 48.4±7.03 which
declined to 32.57±5.62 in PR group whereas in control group ESR
declined from 54.6±4.51 to 38.08±5.88. Mean baseline CRP was
24.84±5.65 which declined to 14.23±5.29 in PR group whereas in
control group CRP declined from 30.56±5.78 to 9.70±4.55. Mean
baseline absolute lymphocyte count was 1588.59±121.65 in PR
group and 1630.34±94.81 in control group. PR occurred as early
as 2 months to 1 year after ATT. Radiological imaging done at the
time of PR in 17 patients showed well deﬁned nodes with hypo-
echoic centre. Cultureswere negative in 28 and 16 had positive AFB
smears(scanty). 18 patients needed surgical exicision anddrainage,
5 and 3 patients were initiated on steroids and pentoxiphylline
respectively.
Conclusion: In conclusion, PR must be considered when
patients with tuberculosis on appropriate ATT presents with wors-
ening symptoms. Low baseline absolute lymphocyte counts with a
surge during PR along with rise in ESR and CRP are described in lit-
erature which however could not be elucidated in our analysis. We
found thatmost of these patients during PR have scanty or negative
smears with negative cultures along with sonographic evidence of
hypo echoic nodes.
http://dx.doi.org/10.1016/j.ijid.2016.02.868
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Background: Tuberculosis (TB) remains one of the world’s
deadliest communicablediseases. In2014,9.6millionpeopledevel-
opedTBand1.5milliondied fromthedisease. EmergenceofMDRor
XDR strains of Mycobacterium tuberculosis (Mtb), coupled with the
lack of effective vaccines and sensitive diagnostic kits has severely
compromised the control of global TB epidemic. Although, (∼90%)
infected subjects are able to contain infection in a sub-clinical
dormant stage known as latent TB infection (LTBI) which consti-
tutes 1/3rd of the world’s population, ∼10% of immunocompetent
infected individuals progress towards active disease during their
life-time. However, factors that promote this transformation aren’t
clearly understood. Additionally, IGRA+ status cannot differentiate
between TB and LTBI. The aim of our study was to identify new
biomarkers that will help distinguish between different TB stages.
Methods & Materials: We evaluated the immunogenicity of
22 Mtb antigens, which included PPD, ESAT6/CFP10, Ag85A/B and
TB10.4 (immunodominant antigens) together with novel latency
(DosR regulon) antigens, resuscitation-promoting factors (rpf),
reactivation-associated, starvation-induced and secreted antigens.
We enrolled 10 subjects from each of LTBI, active pulmonary (PTB)
and extrapulmonary tuberculosis (EPTB) and healthy IGRA- sub-
jects served as controls.Whole bloodwas stimulatedwith antigens
for 7 days followed by IFN ELISA on the supernatants.
Results: Latency antigens (Rv1733, Rv1737 and Rv2029) can be
used to discriminate between LTBI and PTB patients due to 2-4 fold
difference in their IFN responses. EPTB patients showed signiﬁ-
cantly higher IFN responses compared to LTBI and PTB patients
to latency antigens (Rv2626 and Rv2628), RpfA (Rv0867) and RpfD
(Rv2389), IVE-TB antigens (Rv1806, Rv2034 and Rv3353) and reac-
tivation antigen (Rv1131). Rv0934, Rv0440 and TB10.4 elicited
highest IFN response in EPTB patients and a pronounced response
in LTBI compared to PTB patients;whilst responses to ESAT6/CFP10
and PPD were observed in all TB-infected groups. IGRA- healthy
controls showed a comparatively weaker response to most of the
antigens (<40pg/ml).
Conclusion: IFN ELISA is a cheap and useful tool for screen-
ing potential antigenicity in subjects with different TB-infection
states. Combined use of these novel Mtb antigens has the potential
to accurately classify latent versus active TB subjects andmay serve
as promising biomarkers in the future.
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Background: Tuberculosis is an infectious disease caused by
various strains of mycobacteria, the most common one being
Mycobacterium tuberculosis (Mtb). Almost one-third of the total
world population is infected by Mtb and it is the second leading
cause of death due to an infectious agent. Medications are known
for treating TB, but they take long time and development of resis-
tance to known antibiotics is another serious problem. In view of
all these challenges, there is a need to develop newdrug candidates
with novel mechanisms for treating tuberculosis. The pre-clinical
